Medix Biochemica is making a major push to strengthen the future of in vitro diagnostics.
The company has unveiled a $5 million investment to expand its recombinant antigen and cell culture technology capabilities across facilities in Espoo, Finland, and St. Louis, Missouri.
The global diagnostics supplier said the multi-phase expansion aims to deliver more than 60 commercially available recombinant antigen products by 2030, ramping up production capacity as the IVD industry faces mounting pressure on traditional biological material supply chains.
The investment will fund facility upgrades, advanced analytical instrumentation, and the hiring of at least 10 specialized employees across both sites.
Initial development efforts will focus on high-demand clinical areas including hormones, infectious disease and tumor antigens, before moving into large-scale manufacturing, cross-platform validation, and commercial scale-up.
The move comes as diagnostics manufacturers grapple with increasing shortages, inconsistency, and regulatory scrutiny tied to native biological materials and animal-derived inputs. Recombinant antigens are increasingly viewed as a more reliable and scalable alternative for IVD production.
"IVD manufacturers need raw material partners who can support them not just for this product cycle, but for the next decade," said Matt Lee, VP Quality Control Business Unit, of Medix Biochemica.
"Our recombinant expansion is a long-term commitment to supply security, scalable production, and the performance consistency their QC pipelines depend on."
According to the company, the recombinant initiative was built in collaboration with manufacturing partners, with a focus on the technical documentation, stability data, and qualification support required to transition from native to recombinant raw material sourcing.
Beyond supply reliability, the shift is also expected to reduce dependence on animal-derived materials, supporting broader sustainability goals across the global IVD supply chain.
Medix Biochemica said recombinant evaluation packages — including samples, technical data, and pipeline discussions — will be available to qualified partners beginning this year.
